Identifying predictors of overall survival among patients with TMB-low metastatic cancer treated with immune checkpoint inhibitors
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf078 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Camila Braganca Xavier und 7 weiteren Autor:innen. Beteiligte Einrichtung: MD Anderson Cancer Center, Houston, TX, 77030, United States. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Instituto de Ensino e Pesquisa do Hospital Sírio-Libanês.
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs) have significantly advanced cancer therapy, yet their efficacy in tumors with low tumor mutational burden (TMB) remains suboptimal. In this study, we aimed to elucidate the impact of somatic mutations on overall survival (OS) in TMB-low patients treated with ICIs and to explore the potential for personalized treatment selection through machine learning.
Methods
We conducted a comprehensive analysis of 1172 TMB-low (TMB < 10 mutations per megabase) patients with cancer receiving ICIs, examining the association between specific gene mutations and OS. Additionally, we developed a decision tree model (DTM) to predict OS based on clinical features and tumor mutational profiles.
Results
Our findings reveal that mutations in DAXX, HLA-A, H3C2, IGF1R, CTNNB1, SMARCA4, KMT2D, and TP53 are significantly associated with poorer survival outcomes in the multivariate analysis. Remarkably, for renal cell carcinoma (RCC) patients, VHL mutations predicted improved OS following ICI even when adjusted for age, sex, and microsatellite instability (MSI) status in both multivariate analysis and the DTM model.
Conclusions
These results reinforce the prevailing notion that TMB alone does not predict ICI response, highlighting the critical role of individual gene mutations in TMB-low tumors under ICI therapy. Furthermore, our study demonstrates the promise of machine learning models in optimizing ICI treatment decisions, paving the way for more precise and effective therapeutic strategies in this patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MD Anderson Cancer Center, Houston, TX, 77030, United States.
- Hospital Sírio-Libanês, São Paulo, SP, 01308-050, Brazil.
- Innovation Intelligence AI, San Francisco, CA, 94104, United States.
- Princess Margaret Cancer Centre, Toronto, ON, M5G 2C4, Canada.
- Oncoclínicas&CO - Medica Scientia Innovation Research (MedSir), São Paulo, SP, 04538-132, Brazil.
ORCID-Profile: Camila Braganca Xavier
Förderung
- Instituto de Ensino e Pesquisa do Hospital Sírio-Libanês
Zitieren
APA
Braganca Xavier, C., Guardia, G. D. A., Alves, J. P. B., Lopes, C. D. H., Awni, B. M., Campos, E. F., Jardim, D. L., & Galante, P. A. F. (2025). Identifying predictors of overall survival among patients with TMB-low metastatic cancer treated with immune checkpoint inhibitors. The Oncologist. https://doi.org/10.1093/oncolo/oyaf078
Vancouver
Braganca Xavier C, Guardia GDA, Alves JPB, Lopes CDH, Awni BM, Campos EF, et al. Identifying predictors of overall survival among patients with TMB-low metastatic cancer treated with immune checkpoint inhibitors. The Oncologist. 2025. doi:10.1093/oncolo/oyaf078
BibTeX
@article{BragancaXavier2025,
author = {Braganca Xavier, Camila and Guardia, Gabriela D A and Alves, João Pedro B and Lopes, Carlos Diego H and Awni, Beatriz M and Campos, Eduardo F and Jardim, Denis L and Galante, Pedro A F},
title = {Identifying predictors of overall survival among patients with TMB-low metastatic cancer treated with immune checkpoint inhibitors},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf078}
}
EUVIMED